On May 2, 2024, Switzerland’s largest pilot study on recreational cannabis use to date began, regulated by the Swiss Federal Office of Public Health (FOPH). QuickBird Medical is supporting the project by developing a digital platform that accompanies the entire course of the study. The project partner is the Swiss Cannabis Research association.
A digital platform as study companion
The digital platform takes on central functions that make the study process efficient and traceable:
-
Onboarding processes for participants
-
Documentation of the specified quantity limits, sales processes and health status surveys
-
Education & learning content guiding participants towards more responsible use
Alongside its role as a study tool, the platform therefore also acts as a digital education instrument and supports participants in learning to handle cannabis responsibly.
Aim of the study
The study aims to examine the economic and social consequences of a possible legalisation of cannabis. The long-term goal is to provide scientifically sound findings that support the political decision-making process on the legalisation of cannabis. A central aspect of the study is the question of whether healthy and moderate recreational cannabis use is possible.
Size and duration
In total, 5,000 participants will be able to legally purchase cannabis products over a period of five years in cannabis practices and pharmacies set up specifically for this purpose. A control group of 2,500 people will have no access to legal cannabis for the duration of the study.
The study thereby makes an important contribution to the evidence-based debate on cannabis legalisation in Europe.
To the project: Click here
To the LinkedIn post: Click here
QuickBird Medical develops the study platform for Switzerland’s largest cannabis study.